Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...

US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Sanofi pays $15M to license Nurix autoimmune program. Sumitomo transfers Asia units. Gilead cuts 149 jobs, Roche 108 in ...

Nurix Therapeutics (NRIX) announced that Sanofi (SNY) has exclusively licensed an undisclosed Nurix program targeting a previously undruggable ...

Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription ...

Nurix Therapeutics, Inc.’s NRIX share price has dipped by 11.87%, which has investors questioning if this is right time to buy.

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...